Harmony Biosciences Holdings, Inc.
HRMY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | -0.83 | -1.30 | 1.34 |
| FCF Yield | 6.74% | 4.37% | 1.78% | 3.82% |
| EV / EBITDA | 15.44 | 24.36 | 23.75 | 25.52 |
| Quality | ||||
| ROIC | 4.91% | 4.07% | 4.98% | 5.83% |
| Gross Margin | 75.09% | 80.97% | 82.68% | 72.97% |
| Cash Conversion Ratio | 2.14 | 1.99 | 0.75 | 1.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.08% | 15.69% | 16.45% | 17.74% |
| Free Cash Flow Growth | 36.99% | 134.27% | -54.88% | 6.46% |
| Safety | ||||
| Net Debt / EBITDA | -6.50 | -6.29 | -4.65 | -4.09 |
| Interest Coverage | 18.09 | 13.21 | 14.66 | 13.24 |
| Efficiency | ||||
| Inventory Turnover | 8.67 | 6.25 | 5.01 | 7.56 |
| Cash Conversion Cycle | 8.47 | -10.63 | 20.47 | 26.30 |